1. Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
- Author
-
Veit Peter Grunert, Rolando Pajon, Imke Kirste, Udo Eichenlaub, Simon Jochum, Holly Legault, Basel Kashlan, and Sayuri Hortsch
- Subjects
Adult ,Male ,Adolescent ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Article ,Neutralization ,Automation ,Young Adult ,Immunogenicity, Vaccine ,Immune system ,Neutralization Tests ,neutralization assay ,Humans ,Medicine ,Immunology and Allergy ,Seroconversion ,Neutralizing antibody ,Aged ,Original Research ,Messenger RNA ,biology ,business.industry ,SARS-CoV-2 ,quantitative serology ,COVID-19 ,Middle Aged ,Reference Standards ,RC581-607 ,vaccination ,Immunity, Humoral ,Vaccination ,biology.protein ,Female ,ELISA ,Geometric mean ,Antibody ,Immunologic diseases. Allergy ,business ,2019-nCoV Vaccine mRNA-1273 - Abstract
BackgroundThe ability to quantify an immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential. This study assessed the clinical utility of the quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay (ACOV2S) using samples from the 2019-nCoV vaccine (mRNA-1273) phase 1 trial (NCT04283461).MethodsSamples from 30 healthy participants, aged 18–55 years, who received two injections with mRNA-1273 at a dose of 25 μg (n=15) or 100 μg (n=15), were collected at Days 1 (first vaccination), 15, 29 (second vaccination), 43 and 57. ACOV2S results (shown in U/mL – equivalent to BAU/mL per the first WHO international standard) were compared with results from ELISAs specific to antibodies against the Spike protein (S-2P) and the receptor binding domain (RBD) as well as neutralization tests including nanoluciferase (nLUC80), live-virus (PRNT80), and a pseudovirus neutralizing antibody assay (PsVNA50).ResultsRBD-specific antibodies were already detectable by ACOV2S at the first time point of assessment (d15 after first vaccination), with seroconversion before in all but 2 participants (25 μg dose group); all had seroconverted by Day 29. Across all post-baseline visits, geometric mean concentration of antibody levels were 3.27–7.48-fold higher in the 100 μg compared with the 25 μg dose group. ACOV2S measurements were highly correlated with those from RBD ELISA (Pearson’s r=0.938; p80 r=0.933; PsVNA50, r=0.771; PRNT80, r=0.672; all p≤0.0001).ConclusionThe Elecsys Anti-SARS-CoV-2 S assay (ACOV2S) can be regarded as a highly valuable method to assess and quantify the presence of RBD-directed antibodies against SARS-CoV-2 following vaccination, and may indicate the presence of neutralizing antibodies. As a fully automated and standardized method, ACOV2S could qualify as the method of choice for consistent quantification of vaccine-induced humoral response.
- Published
- 2022
- Full Text
- View/download PDF